Exact Mass: 291.0870938
Exact Mass Matches: 291.0870938
Found 95 metabolites which its exact mass value is equals to given mass value 291.0870938,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
NSC 204421
D006133 - Growth Substances > D010937 - Plant Growth Regulators D010575 - Pesticides > D006540 - Herbicides D016573 - Agrochemicals CONFIDENCE standard compound; EAWAG_UCHEM_ID 3097
2,7-Anhydro-alpha-N-acetylneuraminic acid
2-Deoxy-2,3-dehydro-N-acetylneuraminic acid
D004791 - Enzyme Inhibitors
prontosil
C12H13N5O2S (291.07899180000004)
A diphenyldiazene compound having two amino substituents at the 2- and 4-positions and an aminosulphonyl substituent at the 4-position. It was the first antibacterial drug, (introduced 1935) and the first of the sulfonamide antibiotics. C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent
Crufomate
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent CONFIDENCE standard compound; INTERNAL_ID 237; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9553; ORIGINAL_PRECURSOR_SCAN_NO 9552 CONFIDENCE standard compound; INTERNAL_ID 237; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9578; ORIGINAL_PRECURSOR_SCAN_NO 9577 CONFIDENCE standard compound; INTERNAL_ID 237; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9598; ORIGINAL_PRECURSOR_SCAN_NO 9597 CONFIDENCE standard compound; INTERNAL_ID 237; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9618; ORIGINAL_PRECURSOR_SCAN_NO 9616 CONFIDENCE standard compound; INTERNAL_ID 237; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9590; ORIGINAL_PRECURSOR_SCAN_NO 9588 CONFIDENCE standard compound; INTERNAL_ID 237; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9626; ORIGINAL_PRECURSOR_SCAN_NO 9624
(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile
C12H13N5O4 (291.09674980000005)
COVID info from DrugBank, PDB, Protein Data Bank, clinicaltrial, clinicaltrials, clinical trial, clinical trials D000890 - Anti-Infective Agents > D000998 - Antiviral Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Avenalumin III
Phytoalexin isolated from oat (Avena sativa) infected with rust fungus (Puccinia coronata). Avenalumin III is found in oat and cereals and cereal products. Avenalumin III is found in cereals and cereal products. Phytoalexin isolated from oat (Avena sativa) infected with rust fungus (Puccinia coronata).
Hawkinsin
C11H17NO6S (291.07765420000004)
Hawkinsin is a sulfur amino acid identified as (2-L-cystein-S-yl-1,4-dihydroxycyclohex-5-en-1-yl)acetic acid. It is a reactive byproduct of abnormal tyrosine metabolism. Normally, the breakdown of the amino acid tyrosine involves the conversion of 4-hydroxyphenylpyruvate to homogentisate by 4-hydroxyphenylpyruvate dioxygenase. Complete deficiency of this enzyme leads to an inborn error of metabolism called tyrosinemia III. In rare cases, however, the enzyme is still able to produce the reactive intermediate 1,2-epoxyphenyl acetic acid but is unable to convert this intermediate to homogentisate (PMID: 11073718). The intermediate then spontaneously reacts with glutathione to form hawkinsin. Chronically high levels of hawkinsin are associated with hawkinsinuria (characterized by the inability to break down the amino acid tyrosine). Patients with hawkinsinuria excrete hawkinsin in their urine throughout their life. The features of this condition usually appear around the time infants are weaned off breast milk and begin to use formula. The signs and symptoms may include the following: failure to gain weight and grow at the expected rate (failure to thrive), abnormally high acid levels in the blood (acidosis), and fine or sparse hair. Hawkinsin is an acidogen and a metabotoxin. An acidogen is an acidic compound that induces acidosis, which has multiple adverse effects on many organ systems. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Hawkinsin is an organic acid. Abnormally high levels of organic acids in the blood (organic acidemia), urine (organic aciduria), the brain, and other tissues lead to general metabolic acidosis. Acidosis typically occurs when arterial pH falls below 7.35. In infants with acidosis, the initial symptoms include poor feeding, vomiting, loss of appetite, weak muscle tone (hypotonia), and lack of energy (lethargy). These can progress to heart, liver, and kidney abnormalities, seizures, coma, and possibly death. These are also the characteristic symptoms of untreated hawkinsinuria. Many affected children with organic acidemias experience intellectual disability or delayed development. In adults, acidosis or acidemia is characterized by headaches, confusion, feeling tired, tremors, sleepiness, and seizures. Hawkinsin is a sulfur amino acid identified as (2-l-cystein-S-yl, 4-dihydroxycyclohex-5-en-1-yl)acetic acid. Patients with hawkinsinuria excrete this metabolite in their urine throughout their life, although symptoms of metabolic acidosis and tyrosinemia improve in the first year of life. Alterations in the structure and activity of 4-hydroxyphenylpyruvic acid dioxygenase are causally related to two different metabolic disorders, tyrosinemia type III and hawkinsinuria. (PMID 11073718) [HMDB]
Orciprenaline-3-O-sulfate
C11H17NO6S (291.07765420000004)
Orciprenaline-3-O-sulfate is a metabolite of orciprenaline. Orciprenaline is a bronchodilator used in the treatment of asthma. Orciprenaline is a moderately selective beta2-adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on alpha-adrenergic receptors. (Wikipedia)
1,N6-Ethenoadenosine
C12H13N5O4 (291.09674980000005)
2-Deoxy-2,3-dehydro-n-acetyl-neuraminic acid
Carprazidil
C12H13N5O4 (291.09674980000005)
Cloranolol
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AA - Beta blocking agents, non-selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Ethenoadenosine
C12H13N5O4 (291.09674980000005)
Benzo(1,2-b:4,3-b')dipyrrole-2-carboxylic acid, 3,6,7,8-tetrahydro-6-(aminocarbonyl)-5-hydroxy-4-methoxy-
Prontosil
C12H13N5O2S (291.07899180000004)
(+)-toluene-4-sulfonic acid-(1-methyl-2-[2]pyridyl-ethyl ester)|(+)-Toluol-4-sulfonsaeure-(1-methyl-2-[2]pyridyl-aethylester)|(-)-toluene-4-sulfonic acid-(1-methyl-2-[2]pyridyl-ethyl ester)|(-)-Toluol-4-sulfonsaeure-(1-methyl-2-[2]pyridyl-aethylester)
4-amino-5-cyano-7-(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine|4-amino-7(beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile|4-amino-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile|7-Cyano-7-deazaadenosine|NSC-63701|toyocamycin|Vengicide|[(15)N]5-toyocamycin|[2-(13)C]-toyocamycin
C12H13N5O4 (291.09674980000005)
1-((2L)-2-carboxy-5-oxo-1-pyrrolidinyl)-1-deoxy-D-fructose|1-<(2L)-2-carboxy-5-oxo-1-pyrrolidinyl>-1-deoxy-D-fructose|N-(1-deoxy-D-fructos-1-yl)-5-oxo-L-proline|N-(1-deoxy-D-fructos-1-yl)-L-pyroglutamic acid monohydrate
Lysicamine
Lysicamine is an alkaloid antibiotic and an oxoaporphine alkaloid. It has a role as a metabolite. Lysicamine is a natural product found in Annona purpurea, Annona papilionella, and other organisms with data available. A natural product found in Annona glabra.
4-((Ethylanilino)methyl)benzenesulphonic acid
CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2785; ORIGINAL_PRECURSOR_SCAN_NO 2784 CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2801; ORIGINAL_PRECURSOR_SCAN_NO 2800 CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2761; ORIGINAL_PRECURSOR_SCAN_NO 2760 CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2781; ORIGINAL_PRECURSOR_SCAN_NO 2780 CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2778; ORIGINAL_PRECURSOR_SCAN_NO 2777 INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; CONFIDENCE standard compound; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2778; ORIGINAL_PRECURSOR_SCAN_NO 2777 CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5868; ORIGINAL_PRECURSOR_SCAN_NO 5866 CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5916; ORIGINAL_PRECURSOR_SCAN_NO 5914 DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; CONFIDENCE standard compound; INTERNAL_ID 879; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5907; ORIGINAL_PRECURSOR_SCAN_NO 5904 CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5907; ORIGINAL_PRECURSOR_SCAN_NO 5904 CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5930; ORIGINAL_PRECURSOR_SCAN_NO 5929 CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5941; ORIGINAL_PRECURSOR_SCAN_NO 5939 CONFIDENCE standard compound; INTERNAL_ID 879; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5936; ORIGINAL_PRECURSOR_SCAN_NO 5934
Toyocamycin
C12H13N5O4 (291.09674980000005)
An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group. D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC50 value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits CDK9 with an IC50 value of 79 nM[1][2][3].
(1S,4R)-METHYL 4-AMINOCYCLOPENT-2-ENECARBOXYLATE (2R,3R)-2,3-DIHYDROXYSUCCINATE
4-(1-Pyrrolidinylsulforylmenthyl)phenylhydrazine hydrochloride
C11H18ClN3O2S (291.08081980000003)
8-(ethoxycarbonyl)-6-methoxy-7-methyl-6h-[1,2,5]oxadiazolo[4,3-e]indol-3-ium-3-olate
tert-butyl 4-(2-bromoethyl)piperidine-1-carboxylate
Carprazidil
C12H13N5O4 (291.09674980000005)
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
ETHYL 4-FORMYL-2,5-DIMETHYL-1-(2-THIENYLMETHYL)-1H-PYRROLE-3-CARBOXYLATE
N-[(4-methoxyphenyl)methyl]-N-methylbenzenesulfonamide
6-FLUOROQUINOLINE-2,3-DICARBOXYLIC ACID DIETHYL ESTER
4-Quinolinecarboxylic acid, 2-(2,3-dihydro-5-benzofuranyl)
ETHYL 2-AMINO-5-(4-METHOXY-PHENYL)-4-METHYL-THIOPHENE-3-CARBOXYLATE
Radafaxine hydrochloride
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
N-[2-(Piperazin-1-yl)phenyl]methylsulphonamide hydrochloride
C11H18ClN3O2S (291.08081980000003)
tert-butyl 3-(2-bromoethyl)piperidine-1-carboxylate
ethyl (E)-3-(2-chlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)prop-2-enoate
3-THIOPHENECARBOXYLIC ACID, 2-AMINO-4-(4-METHOXYPHENYL)-5-METHYL-, ETHYL ESTER
ethyl (S)-10-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate
2-Propenoic acid, 2-cyano-3-[(3-Methoxy-4-nitrophenyl)aMino]-, ethyl ester
2-[4-(trifluoromethyl)phenyl]-2,3-dihydro-1H-quinolin-4-one
4-allyl-5-(6-methyl-4,5,6,7-tetrahydro-1-benzothien-3-yl)-4H-1,2,4-triazole-3-thiol
Cloranolol
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AA - Beta blocking agents, non-selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
1,N6-Ethenoadenosine
C12H13N5O4 (291.09674980000005)
Toyokamycin
C12H13N5O4 (291.09674980000005)
D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents
(2-l-cystein-S-yl-1,4-dihydroxycyclohex-5-en-1-yl)-acetic acid
C11H17NO6S (291.07765420000004)
2-[amino-[[(3S)-3-azaniumyl-3-carboxylatopropoxy]amino]methylidene]azaniumylbutanedioate
1-(6-aminopurin-9-yl)-3-(hydroxymethyl)-2-oxabicyclo[3.2.0]hept-6-ene-4,5-diol
C12H13N5O4 (291.09674980000005)
(2r,3ar,6r,7r,7ar)-2-[(2s)-2-Amino-2-Carboxyethyl]-6,7-Dihydroxyhexahydro-2h-Furo[3,2-B]pyran-2-Carboxylic Acid
2-(2-methoxyphenyl)-1-methyl-3,5-dinitro-2H-pyridine
4-[2-(4-Fluorophenyl)-5-tetrazolyl]quinoline
C16H10FN5 (291.09201920000004)
2-[2-(4-Tert-butylphenyl)-4-hydroxy-1,3-thiazol-5-yl]acetic acid
4H-3,1-Benzoxazin-4-one, 2-(4-(4-hydroxyphenyl)-1,3-butadienyl)-
(2R)-2-amino-N-[4-chloro-2-[oxo(1H-pyrrol-2-yl)methyl]phenyl]propanamide
3-amino-N-[4-chloro-2-[oxo(1H-pyrrol-2-yl)methyl]phenyl]propanamide
(E)-3-Benzoylmethylene-1-phenyl-2,5-pyrrolidinedione
1-Methyl-4-(1-methoxycarbonyl-2-pyrrolomethylene)-3-methoxycarbonyl-2-pyrazolin-5-one
5-Methyl-2,3-dimethoxycarbonyl-5,6-dihydropyrrolo(1,2-D)(1,2,4)triazocin-6-one
N-acetyl-2,3-didehydro-2-deoxyneuraminic acid
D004791 - Enzyme Inhibitors
(1R,2R,3S,5R)-2-acetamido-7-(1,2-dihydroxyethyl)-3-hydroxy-6,8-dioxabicyclo[3.2.1]octane-5-carboxylic acid
Hawkinsin
C11H17NO6S (291.07765420000004)
A cysteine derivative that is cysteine in which the thiol group is substituted by a [2-(carboxymethyl)-2,5-dihydroxycyclohex-3-en-1-yl]sulfanediyl group. Hawkinsinuria is an inherited disorder which is characterized by the inability to break down the amino acid tyrosine. This results in the finding of certain metabolites in the urine, such as hawkinsin.
GS-441524
C12H13N5O4 (291.09674980000005)
A C-nucleoside analog that is (2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile substituted by a 4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl group at position 2. It is the active metabolite of remdesivir and exhibits a broad range of inhibitory activity against various RNA viruses including HCV, parainfluenza and SARS-CoV.
neodysiherbaine A
A furopyran that is (3aR,7aR)-hexahydro-2H-furo[3,2-b]pyran substituted by carboxy, (2S)-2-amino-2-carboxyethyl, hydroxy and hydroxy groups at positions 2, 2, 6, and 7, respectively (the 2R,3aR,6R,7R,7aR-stereoisomer). A convulsant isolated from the marine sponge Dysidea herbacea.
THS-044
C11H12F3N3O3 (291.08307179999997)
THS-044 binding stabilizes the HIF2α PAS-B folded state, for regulating HIF2 activity in endogenous and clinical settings. Target: HIF2α Limited trypsin proteolysis reveals that both apo and THS-044-bound protein are efficiently cut at R330 in the extended HI loop. In the THS-044 bound state, there appears no additional proteolysis at the remaining candidate trypsin sites. In contrast, these THS-044-protected sites are protease accessible in the unliganded protein, leading its complete degradation. In parallel, NMR-based deuterium exchange measurements revealed a dramatic stabilization of the THS-044-bound protein β-sheet, with some sites experiencing 100-fold enhanced protection factors relative to the ligand-free protein. THS-044 binding stabilizes the HIF2α PAS-B folded state, for regulating HIF2 activity in endogenous and clinical settings. Target: HIF2α Limited trypsin proteolysis reveals that both apo and THS-044-bound protein are efficiently cut at R330 in the extended HI loop. In the THS-044 bound state, there appears no additional proteolysis at the remaining candidate trypsin sites. In contrast, these THS-044-protected sites are protease accessible in the unliganded protein, leading its complete degradation. In parallel, NMR-based deuterium exchange measurements revealed a dramatic stabilization of the THS-044-bound protein β-sheet, with some sites experiencing 100-fold enhanced protection factors relative to the ligand-free protein.